Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

Tue, 20th Dec 2022 14:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

---------

Goodwin PLC - engineer based in Stoke-on-Trent - For the six months ended on October 31, revenue rises 30% to GBP89.3 million from GBP89.3 million from GBP68.9 million the year before. Pretax profit increases by 58% to GBP12.2 million from GBP7.7 million. Workload increases to GBP242 million compared to GBP157 million a year ago. "This increase relates to the materialisation of some of the major projects that the Mechanical Engineering division has been pursuing within the military and nuclear waste re-processing markets", the company notes. Looking ahead, says profitability levels are expected to increase over the next twelve months as a result of increased work load.

---------

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - For the year ended on September 30, reports revenue of GBP18.8 million, up from GBP10.0 million the year ago. Pretax loss narrows to GBP17.8 million from GBP21.4 million. Books an exchange gains on translation of GBP2.3 million from just GBP37,000 the year before. Looking ahead, says excited by its pipeline and prospects, believing in its strategy, team, asset portfolio to secure future funding.

---------

GSTechnologies Ltd - Milton Keynes, England-based fintech and information technology company - Posts a widened loss for the six months ended September 30 to USD1.7 million from a USD1.2 million the year before, as operating loss increases slightly to USD1.2 million from USD1.1 million. Sales for the period drops to USD1.8 million from USD2.3 million a year earlier.

---------

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
11 May 2015 08:15

Redx Pharma Reaches Pre-Clinical Stage With Oncology Compound

Read more
27 Mar 2015 10:35

REPEAT: Redx Pharma Shares Tick Up After AIM IPO As Sanne Prices Its Offering (ALLIPO)

Read more
27 Mar 2015 10:26

Redx Pharma Shares Tick Up After AIM IPO As Sanne Prices Its Offering

Read more
27 Mar 2015 09:43

Redx Pharma enjoys successful AIM debut

Shares in pharmaceutical development company Redx Pharma traded at a small premium upon the company's debut on the London Stock Exchange. The Liverpool-based group began trading on AIM on Friday, having raised £15m in gross proceeds after placing 17.6m shares at 85p each. The company, which has nom

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.